SEARCH

SEARCH BY CITATION

References

  • 1
    Attaran A (1999) Respective contributions of the public and private sector in the development of new drugs: implications for drug access in the developing world. Working paper on the international conference ‘Drugs for communicable diseases: stimulating development and securing availability’ October 14–15, 1999, Paris.
  • 2
    Bobrow M & Thomas S (2001) Patents in a genetic age. Nature 409 , 763764.
  • 3
    Boyce N & Coghlan A (2000) Will patents on human genes encourage research or stifle it? New Scientist 166 , 1515.
  • 4
    Chirac P, Von Schoen-Angerer T, Kasper T, Ford N (2000) AIDS: patent rights versus patient’s rights. Lancet 356 , 502502.
  • 5
    DiMasi J, Seibring MA, Lasagna L (1994) New drug developments in the United States from 1963 to 1992. Clinical Pharmacology and Therapeutics 55 , 609622.
  • 6
    Donald A (1999) Political economy of technology transfer. British Medical Journal 319 , 12981299.
  • 7
    Fortune 500 (2001) Top Performing Industries.http://www.fortune500.com.
  • 8
    Gambardella A, Orsenigo L, Pammolli F (2001) Global Competitiveness in Pharmaceuticals, a European Perspective. Report prepared for the Directorate General Enterprise of the European Commission. http://europa.eu.int/comm/enterprise/library/enterprise-papers/pdf/enterprise_paper_012001.pdf.
  • 9
    Global Forum for Health Research (1999) The 10/90 Report on Health Research 1999, Geneva. http://www.globalforumhealth.org
  • 10
    Grabowsky H & Vernon JM (1994) Returns to R & D on new drug introduction in the 1980s. Journal of Health Economics 13 , 383406.
  • 11
    Haffner M (1999) Orphan drugs: the United States experience. Drug Information Journal 33 , 565568.
  • 12
    Heller MA & Eisenberg RS (1998) Can patents deter innovation? The anticommons in biomedical research. Science 280 , 698701.
  • 13
    IMS (1999) IMS Health Global Insight Reports. http://www.ims-global.com.
  • 14
    Kettler H (1999) Updating the Cost of a New Chemical Entity. Office of Health Economics, London.
  • 15
    Love J (1997) Call for more reliable costs data on clinical trials. Marketletter 13 , 2425.
  • 16
    O'Brien P (1998) The normalisation of the international market for pharmaceuticals: future impacts in emerging markets. In: Medicines and the New Economic Environment (eds F Lobo & G Velasquez). Biblioteca Civitas Economia y Empresa, 1998; Madrid, Espańa, pp. 77–97.
  • 17
    Pécoul B, Chirac P, Trouiller P, Pinel J (1999) Access to essential drugs in poor countries. A lost battle? Journal of the American Medical Association 281 , 361367.
  • 18
    Pflaker K & Brudon P (1998) Programmes Promoting Drug Development: WHO Experiences. WHO/DAP/98.6. World Health Organization, Geneva.
  • 19
    Reich M & Govindaraj R (1998) Dilemmas in drug development for tropical diseases, experiences with praziquantel. Health Policy 44 , 118.
  • 20
    Sachs J (1999) Helping the world’s poorest. Economist August 14 , 1720.
  • 21
    Trouiller P (1996) Recherche et développement pharmaceutiques en matière de maladies transmissibles dans la zone intertropicale. Cahiers Santé 6 , 299307.
  • 22
    Trouiller P, Battistella C, Pinel J, Pécoul B (1999) Is orphan drug status beneficial to tropical disease control? Comparison of the American and future European orphan drug acts. Tropical Medicine and International Health 4 , 412420.DOI: 10.1046/j.1365-3156.1999.00420.x
  • 23
    Trouiller P, Folb P, Weerasuriya K (2001) Legal and regulatory issues affecting drug development for neglected diseases. Working paper of the Drugs for Neglected Diseases Working Group, http://www.neglecteddiseases.org/03.pdf.
  • 24
    Trouiller P & Olliaro P (1999) Drug development output from 1975 to 1996: what proportion for tropical diseases? International Journal of Infectious Diseases 3 , 6163.
  • 25
    Velasquez G & Boulet P (1999) Globalization and Access to Drugs. Perspectives on the WTO/Trips Agreement. WHO/DAP/98.9. World Health Organization, Geneva.
  • 26
    Wehrli A (1997) Globalization and harmonization of regulatory issues: the WHO perspective of developing countries’ needs and perspectives. Drug Information Journal 31 , 895898.
  • 27
    Wilson D, Cawthorne P, Ford N, Aonsonwang S (1999) Global treatment and access to medicines: AIDS drugs in Thailand. Lancet 354 , 18931895.DOI: 10.1016/s0140-6736(99)06114-0
  • 28
    World Health Organization (1999) The World Health Report 1999. WHO, Geneva.